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Advances in genotyping and sequencing technologies have greatly 
revolutionized the analytic methods in genetics research. Due to the dramatically 
decreasing per-genotype cost, millions of variants have been detected and 
genotyped from population-scale data. The findings provide a new insight into the 
human genome, and are continuously shaping our understanding of the genetic 
basis for disease. In this dissertation, I focus on three topics related to 
discovering disease-related variants in genetics studies in the aspects of method 
development and dataset analysis. 
 
In chapter 2, I develop a likelihood-based method, LIME, to detect and genotype 
mobile element insertions (MEIs), a specific type of large insertions, from 
sequencing data. The method generates genotype likelihoods for each MEI using 
simulation that mimics the distribution of reads in regions with and without MEIs 
From both simulated and real sequence data, our method shows better 
sensitivity than existing methods, especially in low-coverage data. 
 
In chapter 3, I present genome-wide association studies and a whole-genome 
sequencing effort of discovering potentially novel loci for colorectal cancer. Using 
an imputation-based meta-analysis strategy, I replicate many previous findings
 xiv	
and provide a list of novel variants and genes for colorectal cancer. In 
collaboration with Fred Hutch Cancer Research Center, we additionally 
sequenced ~3,000 individuals and generated a variant call set. By incorporating 
gene annotation, sequence function prediction and online gene expression 
database, I highlight potentially functional loci for colorectal cancer in the known 
region 12q12 and the novel region 6q21.31. Although it is difficult to obtain new 
significant variants in the absence of extremely large dataset, our analysis 
provides some practical examples to incorporate functional genomics data into 
association analysis and to prioritize potentially functional candidates under 
limited sample size. Additionally, from the variant calling of whole-genome 
sequencing samples, we identified over 50 million variants, half of them being 
novel to the dbSNP database. 
 
In chapter 4, I describe a major update to the meta-analysis software 
RAREMETAL that brings in software engineering improvements and several 
useful new methods for rare variant analysis. The engineering improvements 
make RAREMETAL more computationally efficient. The new methods in addition 
preserve the ability to meta-analysis in unbalanced studies, multi-allelic sites and 







Advances and challenges in modern genetics studies 
In the past decades, advances in genotyping and sequencing technologies have 
greatly revolutionized the methodology in genetics research. Due to the 
dramatically decreasing cost of genotyping, millions of variants have been 
detected and genotyped from population-scale data. Detection of common 
variants and SNPs has been successful during the past several years. The 
findings provide a new insight into the human genome, and are continuously 
shaping our understanding of the genetic basis for disease. However, detecting 
rare and complex variants, such as structural variants, is still difficult, and the 
detection accuracy is insufficient for applying in clinics1. 
 
Accurate detection of genomic variants is the first step in discovering the 
mechanism of diseases. As known from population genetics theory, most 
mutations and polymorphisms are functionally neutral, with little to no effect on 
phenotypes2. With thousands and even millions of novel variants discovered in a 
genetics study, genome-wide association studies (GWAS) have rapidly become 
a standard method for detecting disease-related variants and genes3. During the 
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 past decades, much work has been done to appropriately model the statistical 
association between variants and phenotypes, but for more complicated 
situations, current methods still need to be improved to avoid potential power 
loss. 
 
Genomic variant detection 
In recent years, the rapid development of High-throughput sequencing (HTS) 
provides a new way of detecting genomic variants besides the genotyping array. 
HTS approaches require chopping genomic DNA into shorter size fragments 
(sequencing reads) and sequential detection of the nucleotide composition of 
each fragment thorough sequencing machines. Due to the huge size of the 
human genome and relatively short length of sequencing reads, de novo 
assembly requires massive amounts of computational resources and is in fact 
not possible in practice1. Therefore, to identify the genomic location of reads, a 
common approach is to map them back to reference genome sequences 
 
By comparing sequences between reads and the reference genome, variants are 
discovered from sequencing data. Since sequencing-based studies do not 
require pre-requisite information, it greatly facilitates discovery of rare and novel 
variants. The 1000 Genome Project has discovered over 88 million variants, with 
over half of them novel, while over 70% of them are rare variants with allele 
frequency less than 0.5%11. In this dataset, the heterozygous genotype accuracy 
	 3 
is estimated around 99.4% for Single Nucleotide Polymorphisms (SNPs) and 
99.0% for small insertion and deletions (indels). 
 
With an accurate read aligner and appropriate modeling, most SNPs and indels 
will be reliably discovered by sequence composition of the reads and the 
reference genome{GenomesProjectConsortium:2015gk}. However, Structural 
Variants (SVs), including large-size insertions and deletions, still have much 
lower detection accuracy in sequencing data than SNPs and indels12,13. These 
SVs are mostly longer than the lengths of currently used sequencing reads, and 
as a result, the alternative alleles cannot be reliably reconstructed, which in turn 
leads to loss of detection accuracy as well. Among these SVs, Mobile Element 
Insertions (MEIs) is an important category, with a few reports about its 
association with specific diseases{WoodsSamuels:1989ug}{Stewart:2011bt}. 
Because of shared sequences each family MEIs are easier to detect than novel 
insertions. Therefore, one chapter of this dissertation will focus on improving 
detection accuracy of MEIs from sequencing data.  
 
Imputation and the reference panel 
Large-scale sequencing studies provide a valuable resource of variants, and 
enable researchers to generate reference panels from the variant database. In 
genetics, imputation refers to the statistical inference of unobserved genotypes, 
achieved by utilizing information from known variants and their haplotypes 14. 
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With a well-established reference panel, genotypes of uncovered sites in 
microarray data may be accurately imputed15,16. 
 
Thus imputation provides another efficient and economical method to study rare 
and novel variants under a limited budget. A proportion of samples from a study 
cohort could be sequenced to build an enriched reference panel with rare 
mutations together with the currently existing reference panel. Then, a larger 
study cohort, usually microarray data, could be imputed to this combined 
reference panel. In this way, those variant sites that are not directly genotyped 
will be imputed. Application of this scheme in 1000 Genome studies, and later 
the Haplotype Reference Consortium (HRC) based studies have greatly enlarged 
the power of detecting novel and rare disease-related variants17,18. 
 
Association and causality 
Today, with the greatly reduced cost of genotyping and development of large-
scale variant detection methods, association studies, which compare the 
frequency of alleles in a particular variant between affected and unaffected 
individuals, have become more powerful than traditional linkage analysis19. With 
millions of variants available, a genome-wide association approach surveys most 
of the genome for causal variants, representing an unbiased yet fairly 
comprehensive option that can be attempted even in the absence of convincing 
evidence regarding the function or location of the causal genes20. 
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However, SNPs identified by GWAS are expected to tag genomic regions 
containing correlated SNPs with the trait. It remains an open question of how to 
identify true causal SNPs from these tagged genomic. Fine-mapping efforts 
incorporating functional genomics data to narrow down the range of potentially 
causal SNPs will be cost-effective for laboratory evaluation, especially for LD 
extensive regions with multiple independent SNPs. Additionally, when sample 
size is not enough for rare SNPs GWAS signals to reach genome-wide 
significant threshold, functional genomics data will be helpful to identify true 
causal SNPs from false positives. 
 
Meta-analysis and existing problems 
Recently, meta-analysis, which naturally incorporates cross-study heterogeneity, 
has been successful in many large-size and collaborated GWAS studies21. Meta-
analysis is performed by combining summary statistics across studies and thus 
avoids the data privacy issues in some situations on sharing raw genotypes. 
 
Powerful meta-analysis methods have been proposed, and in ideal situation, they 
may obtain equal power as the joint analysis22,23. However, the underlying 
assumptions of these methods are violated in more real-life situations. For 
example, the basic meta-analysis method suffers substantial power loss when 
the case and control ratio is unbalanced. Current bi-allelic models cannot 
appropriately deal with multi-allelic sites, and results in false-negative 
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associations in such variants. Thus, more work needs to be done to improve 
meta-analysis methods to accommodate different types of data. 
 
Outline of this thesis 
In this dissertation, I focus on three topics related to discovering disease-
associated variants in genetics studies in the aspects of both method 
development and dataset analysis. First, I describe a novel method for detecting 
Mobile Element Insertions (MEIs), a special type of complex variants, from 
sequencing data. Second, I present a genome-wide association analysis of 
colorectal cancer using imputed and/or sequenced data. Third, I present method 
improvements on more complex situations, and covariance matrices storage 
optimizations to the meta-analysis software, RAREMETAL, making it more 
powerful for complicated situations. 
 
In chapter 2, I describe a likelihood-based method, LIME, to detect MEIs from 
sequencing data. The method naturally accommodates cross-sample 
heterogeneity, and generates genotype likelihood to measure the probability of 
each MEI event. From evaluation on both simulated data and deeply-sequenced 
samples 1000 Genome Phase 3, our method shows better performance than 
existing methods, especially in low-coverage data. By applying LIME to 493 
samples from the Sardinia Whole Genome Sequencing Project, I identified 6,537 
MEIs, in which 20 were predicted of having high impact on nearby gene 
expression levels.  
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In chapter 3, I present a genome-wide association analysis of colorectal cancer 
in 26,903 samples imputed on HRC reference panel. Using a meta-analysis 
strategy, we replicated many previous findings and provide a list of novel 
associated variants and genes for colorectal cancer. By incorporating gene 
annotation, sequence function prediction and online gene expression database, 
we highlight potentially functional loci for colorectal cancer. Our results indicate 
that even with a well-established reference panel and superior imputation quality, 
a larger sample size is necessary to discover rare disease-related variants. 
 
Additionally, in chapter 3, as part of the collaboration effort within the Genetics 
and Epidemiology of Colorectal Cancer Consortium (GECCO), we conducted a 
variant calling on 3,061 whole-genome sequenced individuals, aiming to 
generate a consensus call set of variants that are potentially more correlated with 
colorectal cancer. We generated a dataset of 48.7 million variants with superior 
quality, and nearly half of them have never been reported before. 
 
 
In chapter 4, I describe a major update to the meta-analysis software 
RAREMETAL that brings in software engineering improvements and several 
useful new methods for rare variant analysis. The engineering improvements 
make RAREMETAL more computationally efficient. The new methods, 
developed by Dr Dajiang Liu and Dr Jingjing Yang, in addition preserve the ability 
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to meta-analysis in unbalanced studies, multi-allelic sites and generalized linear 
mixed models. With these improvements, RAREMETAL becomes more powerful 
in analyzing real datasets. 
 






1. Ashley, E. A. Towards precision medicine. Nat. Rev. Genet. 17, 507–522 
(2016). 
2. Nei, M., Suzuki, Y. & Nozawa, M. The neutral theory of molecular evolution 
in the genomic era. Annu Rev Genomics Hum Genet 11, 265–289 (2010). 
3. Cantor, R. M., Lange, K. & Sinsheimer, J. S. Prioritizing GWAS results: A 
review of statistical methods and recommendations for their application. 
Am. J. Hum. Genet. 86, 6–22 (2010). 
4. Altshuler, D. et al. The common PPARgamma Pro12Ala polymorphism is 
associated with decreased risk of type 2 diabetes. Nat. Genet. 26, 76–80 
(2000). 
5. Gloyn, A. L. et al. Large-scale association studies of variants in genes 
encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) 
and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated 
with type 2 diabetes. Diabetes 52, 568–572 (2003). 
6. Grant, S. F. A. et al. Variant of transcription factor 7-like 2 (TCF7L2) gene 
confers risk of type 2 diabetes. Nat. Genet. 38, 320–323 (2006). 
7. Guan, W., Pluzhnikov, A., Cox, N. J., Boehnke, M.International Type 2 
Diabetes Linkage Analysis Consortium. Meta-analysis of 23 type 2 
diabetes linkage studies from the International Type 2 Diabetes Linkage 
Analysis Consortium. Hum. Hered. 66, 35–49 (2008). 
8. Altshuler, D., Daly, M. J. & Lander, E. S. Genetic mapping in human 
	 10 
disease. Science 322, 881–888 (2008). 
9. Kretowski, A., Ruperez, F. J. & Ciborowski, M. Genomics and 
Metabolomics in Obesity and Type 2 Diabetes. J Diabetes Res 2016, 
9415645–2 (2016). 
10. Flannick, J. & Florez, J. C. Type 2 diabetes: genetic data sharing to 
advance complex disease research. Nat. Rev. Genet. 17, 535–549 (2016). 
11. 1000 Genomes Project Consortium et al. A global reference for human 
genetic variation. Nature 526, 68–74 (2015). 
12. Zarrei, M., MacDonald, J. R., Merico, D. & Scherer, S. W. A copy number 
variation map of the human genome. Nat. Rev. Genet. 16, 172–183 (2015). 
13. Sudmant, P. H. et al. An integrated map of structural variation in 2,504 
human genomes. Nature 526, 75–81 (2015). 
14. Scheet, P. & Stephens, M. A fast and flexible statistical model for large-
scale population genotype data: applications to inferring missing genotypes 
and haplotypic phase. Am. J. Hum. Genet. 78, 629–644 (2006). 
15. Porcu, E., Sanna, S., Fuchsberger, C. & Fritsche, L. G. Genotype 
imputation in genome-wide association studies. Curr Protoc Hum Genet 
Chapter 1, Unit 1.25–1.25.14 (2013). 
16. Li, Y., Willer, C. J., Ding, J., Scheet, P. & Abecasis, G. R. MaCH: using 
sequence and genotype data to estimate haplotypes and unobserved 
genotypes. Genet. Epidemiol. 34, 816–834 (2010). 
17. Hoffmann, T. J. et al. Imputation of the rare HOXB13 G84E mutation and 
cancer risk in a large population-based cohort. PLoS Genet. 11, e1004930 
	 11 
(2015). 
18. McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype 
imputation. Nat. Genet. 48, 1279–1283 (2016). 
19. Risch, N. & Merikangas, K. The future of genetic studies of complex human 
diseases. Science 273, 1516–1517 (1996). 
20. Hirschhorn, J. N. & Daly, M. J. Genome-wide association studies for 
common diseases and complex traits. Nat. Rev. Genet. 6, 95–108 (2005). 
21. Scott, L. J. et al. A genome-wide association study of type 2 diabetes in 
Finns detects multiple susceptibility variants. Science 316, 1341–1345 
(2007). 
22. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-
analysis of genomewide association scans. Bioinformatics 26, 2190–2191 
(2010). 
23. Liu, D. J. et al. Meta-analysis of gene-level tests for rare variant 






LIME: a likelihood-based Mobile Element Insertion 
detector for sequencing data1 
 
Introduction 
Mobile elements are DNA sequences that can insert themselves along the 
genome1. It is estimated over 40% of the human genome consists of mobile 
elements or mobile element derived sequences2. Only a few of the mobile 
elements in the genome are still mobilized; the remaining elements are slowly 
“decaying” through mutation1,3,4. 
  
Based on their consensus sequences, mobile elements are classified into 
multiple families. Among them, ALU, LINE1 and SINE/VNTR/ALU (SVA) are the 
most actively transcribed ones in the human genome1. A human genome is 
estimated to harbor ~1,500 non-reference mobile element insertions (MEIs), 
including ~1200 ALUs, ~200 LINEs, and ~100 SVAs5. These MEIs can disrupt 
																																																								
     The work presented in Chapter 2 will be submitted as Chen S, Othman M, Abecasis G. “LIME: 
a likelihood-based Mobile Element detector from sequencing data”. 
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normal gene function or even generate new genes. Some have been shown to 
cause diseases such as hemophilia A6, Crohn’s disease7, and cancer8,9. 
 
Next generation sequencing has greatly facilitated the study of MEIs at both 
individual and population levels. With appropriate bioinformatics approaches, 
MEIs could be detected out of the great amount of sequencing reads. The most 
common method for detecting MEIs is to identify reads that are partially aligned 
to known mobile element sequences, and then identify regions of the genome 
where clusters of these reads (or their mate pairs) align10. Unfortunately, this 
method suffers substantial power loss when samples are sequenced at low 
coverage and does not easily accommodate heterogeneity in sequence data 
between samples11. 
 
Here, we present our likelihood-based MEI detector (LIME). LIME compares the 
distribution of mapped reads between regions with and without an MEI, and 
generates genotype likelihoods that naturally accommodate heterogeneity 
between samples in coverage, read mapping rates, and insert sizes. LIME does 
not use fixed thresholds when examining reads supporting each event; thus 
detection power in low coverage samples is greatly improved. By applying LIME 
to a subset of Sardina Whole Genome Sequencing Project12, we generated a call 





Consider an experiment where short paired-end reads are sequenced and 
mapped to a reference genome. After mapping, most read pairs map close 
together with an expected orientation and distance. However, for regions with an 
MEI, read pair arrangements might deviate from this pattern. For example, some 
read pairs may have one end partially or entirely mapped to a mobile element 
sequence elsewhere in the genome, which may result in abnormal insert size or 
strand orientation between the two ends. To systematically summarize read pair 
distributions in each region, we classify mapped read pairs into 18 categories 
based on insert sizes, orientation and mapping to consensus mobile element 
sequences (Table 1.1). In an ideal situation, for the genomic regions with no MEI 
or other genomic variation, all reads will be properly mapped with a normal insert 
size or strand orientation. For regions with MEIs, there will be an excessive 
number of other types of reads (Table 1.2). 
 
Construct known genotypes to model read type distribution 
Our LIME method tries to fully interpret the distribution of the 18 read-types in 
each region. This distribution is specific to each sample because it depends on 
characteristics of library preparation such as read length and insert size. LIME 
uses simulation to construct a sample specific model for the distribution of read 
types in regions with and without MEIs. These distributions are then used to 
calculate the genotype likelihood for each potential MEI. 
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To model the distribution of read-types in regions with an MEI, we construct a 
modified reference genome sequence where several reference ALUs, L1s and 
SVAs are spliced out (sections below will discuss selection criteria). Relative to 
this modified reference sequences, samples are expected to be homozygous for 
these MEIs, one in each spliced region. For each sample, we remap reads to this 
modified reference and summarize the distribution of the 18 read types in each of 
the spliced regions. 
 
Next, we bin the modified reference genome into 600-bp windows (typically, we 
recommend setting this window size to be at least double the average insert 
size). We label each window i in this modified genome that overlaps an artificially 
constructed MEI, as Gi = 1/1; we label remaining windows Gi = 0/0. Reads within 
each window are classified into the 18 read types. Then, for each constructed 
window i, we define the total number of reads as ni and the number of reads 
belonging to type r as nir. Then, this window i specific frequency of read type r is 
!!" = !!"!! . 
 
Sliding window analysis in real sample 
In original mapping results, we slide a fixed size window along the genome, with 
window size the same as described in sections before. In each window, reads 
are classified into the 18 read types, too. For each window j, we define the total 
number of reads as cj and the number of reads of type r as cjr. We calculate 
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genotype likelihoods for each window j based on total R reads within it -- first by 
comparing the read distribution of window j to artificially constructed windows 
with homozygous MEIs, then to windows with reference genotypes, and finally to 
a composite of the two. For each underlying genotype, we iterate through all Ni 
constructed windows i in the modified genome, and define: 














Specifically, to construct windows that contain heterozygous MEIs (which we 
term as Gi = 0/1), we match constructed windows i0 with Gi = 0/0 and windows i1 
with Gi = 1/1 based on sequence mappability and GC content. Read counts in 
the two windows are proportionally adjusted so that total read counts of the two 
windows are the same.  Then we define window specific frequency of read type r 
in constructed heterozygotes window i as: 
!!! = 0.5!!!! + 0.5!!!! 
Therefore, genotype likelihood for heterozygotes is defined as: 







For the specific window j in the originally mapped data, the prior probability of 
genotype Gj, ! !! , is derived using Expectation-Maximization algorithm with or 
without assuming Hardy-Weinberg Equilibrium13. Posterior probability of 




! !! ! !"#$!,!,…,!|!!
! !! ! !"#$!,!,…,!|!!!!
 
 
The genotype of window j is finalized with the highest posterior probability. 
Note that genotype likelihood of those constructed homozygous MEI windows in 
the modified reference genome can be calculated under the same scheme, 
which is used as an estimate of MEI detection power in each sample. 
 
When remapping reads to the mobile element consensus sequence, LIME 
additionally generates site-level features of each MEI, such as length, depth and 
number of supporting reads. MEI length is estimated as the distance between 3’ 
and 5’ mapped positions in their corresponding mobile element consensus 
sequence. In our preliminary analysis, we found that non-MEI genomic variants 
might also be identified as non-reference genotypes, since their read type 
distribution is somewhat different from regions with reference genotypes. In order 
to filter out such false positives, we applied the following empirical rules that are 
adapted from other methods15,16: 1. Estimated MEI length should be longer than 
100 base pairs. 2. MEI supporting read counts on either side of the window 
should be no more than 4 times of the other side. 
 
Generate simulated dataset to evaluate LIME performance 
We generated a simulated sequence by randomly inserting 2,000 ALU and 2,000 
L1 consensus sequences into GRCh37 chromosome 17. L1 sequences are 
randomly truncated from 3-prime ends. Pair-ended Illumina Hi-seq 2000 reads 
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were generated against this simulated sequence using illumine read simulator 
ART17. These simulated reads were mapped back to the original hs37d5 
reference sequence using mapper BWA MEM18. BamUtil19 was applied to 
mapping results to mark PCR duplicates and recalibrate mapping quality. LIME 
and three published MEI detection methods, RetroSeq15, Tangram20 and 
Mobster16, were applied to this dataset, with details in Supplementary Text. 
 
With the detection results from the four methods, MEI detection power for each of 
them is measured as the number of detected MEIs that are within 600 base pair 
range of simulated MEIs, divided by the total number of simulated MEIs. The 
false discovery rate is measured as the number of detected MEIs that are not 
within this range of simulated MEIs, divided by the total number of detected MEIs 
by this method. 
 
Results 
Performance on simulated data 
In the simulated dataset with read lengths of 100 base pairs, LIME, along with 
RetroSeq, showed better detection power over the other two methods (Figure 
2.1). LIME and RetroSeq had similar performance in detecting ALUs, with 60% 
power in detecting homozygotes in 2x coverage. ALU detection powers of these 
two methods were saturated at the coverage of 5x in homozygotes, which is 
equivalent to 10x in heterozygotes. Tangram ALU detection power was saturated 
at a higher coverage of 15x. In low-coverage data, LIME also has improved 
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detection power for L1s. In 2x data, LIME had higher power of 30% in 
heterozygotes and 50% in homozygotes, compared to RetroSeq’s 20% in 
heterozygotes and 41% in homozygotes. Results from 75 bp simulated data 
shows similar pattern for the four methods (Figure S2.2). On the other hand, 
LIME had less than 1% false discovery rate in all simulated data (Figure S2.1, 
S2.3).  
 
Breakpoint detecting accuracy is an important measurement of variant calling 
method performance as well20,21. In 20x-simulated data, we calculated the 
distance between estimated and true MEI breakpoints across all four methods 
(Figure 2.2). For LIME, Tangram and Mobster, most distances were smaller than 
20 bp in simulated dataset, indicating their good performance in refining MEI 
breakpoints. 
 
Analysis on 1000G deep-sequenced trio samples 
The 1000G Phase 3 deep-sequenced European trio samples (NA12878, 
NA12891, NA12892) have been widely used to measure performance of 
genomic variants detecting methods22. We applied LIME and Mobster to these 
three samples using their default settings. RetroSeq and Tangram detecting 
results of this dataset were downloaded from the RetroSeq Wiki page15. 
 
Overall, the four methods had similar numbers of detected MEIs in each 
individual, with RetroSeq had fewer number of detected MEIs than the other 
	 20 
three methods (Table S2.1). To estimate the percentage of covered PCR 
validated events as a rough estimate of detection power, we downloaded the list 
of these samples’ PCR validated MEIs 22 from 1000 Genome ftp and lifted over 
their chromosome positions accordingly. We show that LIME (99.1%) and 
Mobster (99.4%) have the highest percentage of covered validated MEIs (Table 
2.3). 
 
At the same time, we used the parent-child inconsistent rate of MEIs to roughly 
evaluate the false discovery rate of our method (Table 2.4). LIME has the lowest 
overall discordance rate (7.0%) across all four methods, compared to RetroSeq 
(7.3%), Mobster (9.6%) and Tangram (11.6%). At the same time, LIME’s L1 
discordance rate (9.5%) is greatly improved over RetroSeq (11.4%), Mobster 
(23.3%) and Tangram (11.4%). 
 
Experimental validation 
We applied LIME to 20 samples from the Age-related Macular Degeneration 
(AMD) Whole Genome Sequencing Project. All samples consist of 100 bp pair-
ended reads, with sequencing coverage ranges from 2x to 7x. Basically, 3,634 
ALUs, 417 L1s and 31 SVAs were identified from the dataset. 11 ALU sites were 
randomly picked and PCR-validated in all 20 samples. 220 PCR reactions were 
performed in total. The false positive rate, estimated as the number of false 
positive sites across all 20 samples divided by the total number of discovered 
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MEIs, is 5.4%. The detection power, measured as the number of discovered true 
positive sites divided by the total number of true positive sites, is 87.7%.  
 
Additionally, for 8 homozygous MEIs, we compared their LIME estimated lengths 
to their Sanger-sequencing measured true lengths. In 7 out of 8 the MEIs, the 
difference between the true and the estimated MEI length was smaller than 20 
base pairs. Only one MEI was estimated as 154 bp but was actually 303 bp in 
Sanger sequencing results. 
 
Analysis on Sardinia dataset 
We applied LIME to 493 low-coverage sequenced samples in Sardinia Whole 
Genome Sequencing Project12. All samples were pair-ended sequenced with 100 
bp read length on each end, with a median coverage of 4.6 (Table 2.5). In this 
dataset, LIME found 6,215 ALUs and 322 L1s. In average, we detected 757 
ALUs and 69 L1s from each individual. Our MEI call set showed similar allele 
frequency spectrum as previously reported SNP call set12 (Figure 2.3). Both call 
sets have an excessive number of low-frequency variants. 
 
We annotated these MEIs and predicted their functions using SnpEff23. Three 
MEIs were annotated as “high impact”, indicating their potentially disruptive 
impact on the coding genes. Seventeen MEIs were annotated as “moderate 
impact”, showing they’re probably non-disruptive variant that might change 
protein effectiveness. Around one thousand variants were annotated as “low 
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impact”, meaning most of them are likely harmless. Others are either intergenic 
or located in non-coding genes. This indicates potential functionality of some 
MEIs, which may be further revealed in additional analysis. 
 
Discussion 
We developed a likelihood-based method to detect MEIs from whole-genome 
sequencing data. Based on simulation using real reads from each sample, our 
likelihood incorporates sample-specific features and provides a quantitative way 
of measuring how likely an MEI event is true. On simulated datasets and 1000G 
deep-sequenced samples, LIME shows better performance to other methods, 
especially in low-coverage data. 
 
Our modeling of MEI likelihood may be further implemented incorporating other 
features such as mapping scores. With the current classification methods, reads 
within same category contributes equally to an MEI’s likelihood, no matter how 
high their mapping score to the MEI consensus sequence are. A more detailed 
classification of reads incorporating mapping scores may be a future direction to 
improve LIME, and will be especially useful in situations where longer reads have 
various lengths of split-mapped ends. 
 
Under current short-gun sequencing technology, MEI calling accuracy is still 
much lower than short variants. Factors such as data quality, batch effect and 
sequencing depth may greatly affect MEI detector performance. In population-
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scale data, external haplotype information could be help to improve genotyping. 
Using high-quality SNPs and prior information of recombination rate, low-quality 
genotypes could be corrected by their nearby markers. With our LIME approach, 
MEIs could be combined with SNPs for further refinement, thus improved MEI 








Figure 2.1 MEI detection power in simulated data across four methods (100 
bp pair-ended reads) 
The red line shows the power of LIME, while the other three colored lines show 
power of three most widely used methods. Power is calculated as the number of 
detected MEIs divided by the number of simulated MEIs in the modified 







Figure 2.2 Breakpoint detection accuracy of four methods in simulated data 
The breakpoint detection accuracy was estimated as the base pair distance 
between true breakpoint and the estimated breakpoint simulated data with 
homozygous ALUs and 100 bp pair-ended reads under 20x coverage. LIME 
shows good breakpoint detection accuracy as well as Tangram and Mobster, 
with most of distances between the true and the estimated breakpoints smaller 







Figure 2.3 Log-scale allele frequency spectrums of SNPs and MEIs in 
samples from Sardinia Whole-genome Sequencing Project (493 samples) 
Overall, frequency spectrums of MEIs and SNPs (provided by Sidore et al12) are 








Table 2.1 The 18 pre-defined read pair types in LIME 
Read pair types were defined based on the following criteria:  
1. We set the distance threshold as the sample’s insert size plus 3 times of the 
standard deviation of the insert sizes of the sample. Of the mapped distance 
between two ends of the read pair is smaller than the distance threshold, and 
have the correct orientation, it is named “properly mapped”; otherwise if the 
distance is smaller than the distance threshold, it is named “discordantly 
mapped”. 
2. For properly mapped read pairs, if one end is split-mapped and the clip is 
longer than the defined minimum clip length: if the clip is at the 5’ end of the read, 
it is named as “left clip”, otherwise it is “right clip”. If the clip is mapped to an MEI 
consensus sequence, it is marked as “Mapped to MEI”, otherwise marked as 
“Not mapped to MEI”. 
3. Similarly, for read pairs with one end not mapped, the “Mapped to MEI” 
condition is decided by the mapping state to the MEI consensus sequence for the 
unmapped end. 
4. For discordantly mapped read pairs, the end mapped to the examined 
genomic region is named “Anchor”. Similarly, the “Mapped to MEI” condition is 











Read mapped to 
plus strand 
Left clip 
Mapped to MEI 
Not mapped to MEI 
Right clip 
Mapped to MEI 
Not mapped to MEI 
Read mapped to 
minus strand 
Left clip 
Mapped to MEI 
Not mapped to MEI 
Right clip 
Mapped to MEI 




Anchor mapped to plus strand 
Mapped to MEI 
Not mapped to MEI 
Anchor mapped to minus strand 
Mapped to MEI 
Not mapped to MEI 
Read pairs 
with one end 
not mapped 
Anchor mapped to plus strand 
Mapped to MEI 
Not mapped to MEI 
Anchor mapped to minus strand 
Mapped to MEI 




Table 2.2 Average proportions of read pair types in windows of 
homozygous MEIs in NA12878 of 1000 Genome Project Phase 3 
For each identified MEI from deep-sequenced individual NA12878, we classified 
and counted read pair types within a 600 bp window (centered at each MEI 
breakpoint). An excess of clipped and discordantly mapped reads was observed 
in these windows. Note that “mapped to MEI” reads were majorly used to detect 
MEIs from most software. 
 
Read pair type 
Average 
proportions of 
pairs in window 
Properly mapped 0.430 
Properly mapped with clip length < minimum clip length 0.018 
Properly mapped with clip >= minimum 
clip length 
Mapped to MEI 0.043 
Not mapped to 
MEI 
0.000065 
Discordantly mapped read pairs and 
Read pairs with one end not mapped 
Mapped to MEI 0.336 







Table 2.3 Number and percentage of covered PCR-validated MEIs in 1000 
Genome Phase 3 deep sequenced trio samples (NA12878, NA12891, 
NA12892) 
LIME and the other three methods were applied to the three 80x samples. LIME 
and Mobster has better coverage of PCR-validated MEIs, which implies higher 
detection powers of these two methods. 
 
 
# Total Covered 
(%Covered) 
# ALU Covered 
(%Covered) 
# L1 Covered 
(%Covered) 
Lime 460 (98.1%) 441 (99.1%) 20 (83.3%) 
RetroSeq 451 (96.2%) 435 (97.8%) 18 (75.0%) 
Tangram 455 (97.0%) 436 (98.0%) 20 (83.3%) 






 Table 2.4 Parent-child inconsistency of MEIs in 1000 Genome Phase 3 
deep sequenced trio samples (NA12878, NA12891, NA12892) 
The count of parent-child inconsistent MEIs is calculated as the number of MEIs 
in the offspring (NA12878) but not existing in any of the parents (NA12891 and 
NA12892). LIME has the lowest overall inconsistent rate, and the lowest 
inconsistent rate in L1. 
 
Caller 
# Inconsistent ALUs 
(%Inconsistency) 





Lime 95 (6.9%) 13 (9.5%) 107 (7.0%) 
RetroSeq 51 (4.7%) 41 (23.5%) 92 (7.3%) 
Tangram 155 (11.6%) 26 (11.4%) 181 (11.6%) 





Table 2.5 Summary of sequencing characteristics in Sardinia Whole 
Genome Sequencing samples (n = 493) 
Overall the Sardinia samples were sequenced in low-coverage, with an average 
coverage of 4.6x. The samples have consistent insert size but vary in mapping 
read and the proportion of properly mapped reads, which implies batch effect and 
increased error rate in part of the samples. 
 
 Mean Median Minimum Maximum 
Depth (x) 4.9 4.6 4.0 9.8 
Mapping rate 97.4% 97.6% 94.3% 99.5% 
Properly 
mapped read 
94.3% 94.1% 86.6% 98.6% 






Optimizations on LIME internal simulation 
When constructing known genotypes to mimic read type distribution, it is 
computationally expensive to remap all reads back to the modified reference 
genome. For efficiency, we only remap pair-end reads around each spliced 
region. This is substantially faster and results in similar accuracy as remapping 
all reads. 
 
Secondly, considering there are less than 2,000 MEIs per individual genome, it is 
not cost-effective to analyze all windows across the genome. In our simulation 
results (discussed below), we found that, even when the coverage is as low as 2, 
all MEIs had at least one read pair with abnormal insert size and one end 
discordantly mapped to a mobile element sequence elsewhere in the genome. 
Therefore, instead of analyzing all windows along the genome, LIME only 
analyzes regions with at least one such read pair. 
 
Thirdly, to measure impact of the number of constructed windows on genotyping 
accuracy, we used a simulation approach to generate 2000 ALUs on 
chromosome 17 under coverage of 2 and 5. (The simulation method will be 
discussed in section 3.1.) We tested LIME detection power with different number 
of constructed homozygous MEI windows and calculated the percentage of 
identified MEIs using 10,100,300 and 800 constructed homozygous MEI 
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windows. When using only 10 reference windows, 47% and 50% detection power 
was lost in 2x and 5x data, respectively. Using the same dataset, we then tested 
MEI detection power using 10,100,1000,5000, and all constructed reference 
genotype windows on chromosome 20. When using 10 reference windows, 37% 
and 3% detection power was lost in 2x and 5x data, respectively. These results 
indicate that an insufficient number of constructed windows will lower detection 
power. Therefore, to maintain detection power and minimize computational cost 
at the same time, we set 300 and 5000 as the default number of constructed 
windows with homozygous MEI and reference genotype in LIME, respectively. 
 
Commands for evaluation of LIME, RetroSeq, Tangram and Mobster 
Command for LIME: 
LIME –SampleList <chr20-sample.list> -OutVcf <refstat> -SiteVcf <empty file> --
statOnly 
LIME –SampleList <sample.list> -OutVcf <output> -rSingle <refstat> -Chr 17 
 
Command for RetroSeq: 
retroseq.pl -discover -bam <bam> -output candidates.tab -q 10 -len 30 -refTEs 
ref_types.tab -eref probes.tab –align 
retroseq.pl -call -bam <bam> -input candidates.tab -ref hs37d5.fa -output 
<output> -reads 1 -q 10 -region 17 –hets 
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Tangram only works on MOSAIK mapped results, so tangram_bam needs to be 
used first to convert bwa mapped bams to MOSAIK mapped ones: 
tangram_scan -in bam-list.txt -dir scan_out -mf 0 
 
Tangram is applied using following command: 
 
tangram_detect -lb scan_out/lib_table.dat -ht scan_out/hist.dat -in bam-list.txt -rg 
17 -ref hs37d5.indexed.ref -out <out> -gt -bp -mcs 1 -mq 10 -smq 10 -rpf 1 -srf 1 
 
Mobster throws an exception when processing reads that are marked as PCR 
duplicates or supplementary mapping. Therefore, we remove those reads from 
simulated data and apply Mobster using the following command: 
 
java –jar Mobster.jar –properties <properties> –in <bam> -out <out> -sn 
<sample> 
 
Here, in mobster property, we set minimum required supporting reads to one 
instead of default five to increase detection power in low-coverage data. 
 
PCR protocols 
DNA concentration was around 50 ng/ul. PCR primers were designed used NCBI 
Primer-Blast for the regions of interest spanning various chromosomal regions. 
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We used NEB 2x master mixes of OneTaq high fidelity hot start enzyme either 
with standard buffer or GC buffer based on the sequence of interest. Primers 
stocks were made to 100 uM and working dilutions were used at 10 uM.  
Strip tubes were centrifuges briefly and place in PCR machines PE 9700 with the 
following run program: 
1 cycle at 94 °C, 2 minutes 
10 cycles at: 94 °C, 20 seconds; 58 °C, 30 seconds; 68 °C, 45 seconds 
Followed 25 cycles at: 94 °C, 20 seconds; 60 °C, 30 seconds; 68 °C, 45 
seconds 
1 cycle at 68 °C, 10 minutes 
Hold at 4 °C 
After PCR amplification, 1 ul of each was run on the Agilent Bioanalyzer 2200 
TapeStation machine with the relevant ladders. Samples were submitted to the 
University of Michigan Sequencing Core for Sanger Sequencing using the 
forward and the reverse primers. Run files were analyzed using the GCC demo 
software Sequencer version 5.1. 
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Supplementary Figures and Tables 
 
Supplementary Figure 2.1 MEI false discovery rate (FDR) in simulated data 
(100 bp pair-ended reads) 
We estimated the false discovery rate as the number of detected MEIs not 
overlapped with simulated MEIs divided by the number of detected total MEIs. 






Supplementary Figure 2.2 MEI detection power in simulated dataset (75 bp 
pair-ended reads) 
For all 4 methods, deeper coverage results in high MEI detection power. In lower 
coverage situations, LIME and RetroSeq have better detection power. Detection 
power of the 4 methods saturated at a certain coverage. These trends are similar 






Supplementary Figure 2.3 MEI false discovery rate (FDR) in simulated 
dataset (75 bp pair-ended reads) 







Supplementary Table 2.1 Numbers of detected MEIs in 1000 Genome Phase 
3 deep sequenced samples (ALUs, L1s and SVAs) 
Overall the four methods have similar number of detected MEIs in each sample. 
RetroSeq is most conservative while the other three methods have more similar 










Caller NA12878 NA12891 NA12892 
Lime 1549 1665 1588 
RetroSeq 1222 1139 1153 
Tangram 1511 1359 1369 
Mobster 1568 1424 1392 
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Discovery of novel variants associated 
with colorectal cancer3 
 
Introduction 
Colorectal cancer is the fourth most common type of cancer. With an estimate of 
135,430 new cases in 2017, consisting of 8% all new cancer cases in the United 
States1. In recent years, under the framework of genome-wide association 
studies (GWAS) researchers have discovered many common variants and genes 
statistically associated with colorectal cancer2-11. For example, the mutation of 
rs16892766 at 8q23.3 leads to overexpression of cell growth factor EIF3H, which 
greatly increases the risk of colorectal cancer7,12,13. The mutation of rs4939827 at 
gene SMAD7 has functional impact on the Wnt signaling pathway and is highly 
associated with colorectal cancer risk4. These findings provided new insights into 
																																																								
									Part of this work in Chapter 3 will be submitted as: 
        Chen S, Huyghe J, Qu F, Lin Y, Peters U, Abecasis G. “Discovery of novel risk variants for 
colorectal cancer from an imputation-based study”. 
        The WGS work in Chapter 3 has been included in the publication as: 
        McCarthy S, Das S, …, Chen S, …, Durbin R, Abecasis G. “A reference panel of 64,976 
haplotypes for genotype imputation”, Nat Genet, 2016 
        Rashkin S, Jun G, Chen S, Abecasis G, “Optimal sequencing strategies for identifying 
disease-associated sigletons”, Plos Genetics, 2016 
        The HRC imputed dataset in Chapter 3 has been included and submitted as: 
        Bien S, Auer P, …, Chen S, …, Hsu L. “Enrichment of colorectal cancer associations in 
functional regions: insight for using epigenmocs data in the analysis of the whole genome 
sequence-imputed GWAS data”. Plos Genetics, 2016 
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specific genes and regulatory regions, and revealed the importance of previously 
ignored pathways. 
 
Even with these achievements, there still remain some unsolved questions. The 
heritability of colorectal cancer varies from 7.4% to 35%14-16, indicating the 
contribution of unknown variants. Recent progress in genotyping technology and 
statistical methods has made larger-scale imputation-based studies possible, but 
few studies have applied these kinds of methods to colorectal cancer. 
 
Here, we conducted a genome-wide association analysis in 22 million Haplotype 
Consortium Reference Panel (HRC)17 imputed SNPs from 26,903 individuals 
across 14 studies. Compared to the 1000 Genome Phase 3 reference Panel, the 
newly released HRC panel has an unprecedented density and a higher rare 
variant imputation quality17. We identified six candidate regions and one gene 
potentially associated with colorectal cancer. By integrating functional annotation, 
sequence function prediction, tissue-specific expression quantitative trait loci 
(eQTL) data and meta-analysis, we highlighted several SNPs in known risk 
regions as potentially functional candidates. 
 
Additionally, as part of the collaboration effort within the Genetics and 
Epidemiology of Colorectal Cancer Consortium (GECCO), we conducted a 
variant calling on 3,061 whole-genome sequenced individuals, aiming to 
generate a consensus call set of variants that are potentially more correlated with 
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colorectal cancer. We generated a dataset of 48.7 million variants with superior 
quality, and half of them are novel to dbSNP18 build 145. 
 
Materials and Methods 
Data processing and imputation 
Our dataset consists of 12,186 controls and 14,717 cases, coming from 6 
genotyping platforms and 14 studies. Detailed information about the studies and 
genotyping methods can be found in Table S3.1. All individuals were identified as 
Europeans (Figure S3.1) 19,20. Samples from the same genotyping platform was 
merged and imputed onto Haplotype Reference Consortium (HRC) reference 
panel on Michigan Imputation Server21. 
 
Statistical analysis 
For phenotypes, individuals with or without colorectal caner were coded as 0 or 
1, respectively. Adjusted covariates included age, sex, study, batch information 
(if applicable) and first three genotype PCs estimated by PLINK22. Covariates 
were first regressed out from the phenotypes. We used the expected number of 
alternative alleles (dosage) for unbiased estimates23. Single-variant analysis was 
performed under a linear mixed model framework of binary score test 
extensions24 using EPACTS25 (Figure S3.3). Meta-analysis was performed by 
summarizing p values and Z-scores in METAL26 (Figure S3.2, S3.4). 
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For the gene-based test, we conducted a burden test with equal weight27 using 
Raremetal28,29 (Figure S3.5). We used LocusZoom30 to demonstrate potentially 
significant loci. 
 
For single-variant meta-analysis, we used p value < 5x10-8 as the genome-wide 
significance threshold. As mentioned by previous studies, at p value < 5x10-7 
there still exist possible associated variants in European populations31-36. 
Therefore, we also reported variants with p value smaller than 5x10-7 as potential 
candidates. For the gene-based test, as we tested 18,677 genes, 2.7x10-6 was 
used as the genome-wide significance threshold at the significance level of P < 
0.05 after multiple corrections. 
 
Functional annotation 
Using EPACTS, we annotated all variants (both genotyped and imputed) into six 
categories: synonymous, nonsynonymous, exon, intron, stop gain and stop loss. 
To search for causal SNPs, we built and optimized an fGWAS37 model 
incorporating genomic annotations and meta-analysis summary statistics. The 
final model, which has likelihood maximized, includes three annotations: exon, 
synonymous and stop gain. Previous fGWAS studies have suggested using 
posterior probability of association (PPA) greater than 0.9 as the threshold for 
causal SNPs. However, in other previous studies, PPA>0.2 was also widely 




Sequence functionality prediction 
We used a Support Vector Machine (SVM) classifier, deltaSVM40, to predict 
functions of each SNP based on its reference and alternative alleles, together 
with its 11 base-pair flanking sequences on both sides. We used ENCODE 
tissue-specific DNaseI peak information on the UCSC Genome Browser41-43 to 
generate training sets for the classifier. Peak were centered and normalized to a 
uniformed length of 500 base pairs. Sorted by p values in ascending order, we 
selected the first 100,000 peaks as the positive training set. To construct 
negative training sets, we binned the rest of the genome into 500 base-pair 
windows, and randomly sampled sequences by their matching GC content and 
fraction of repeats against those in the positive training set. 
 
Test eQTLs 
First we selected variants with meta-analysis p value less than 10-5 and absolute 
value of deltaSVM score higher than 1. The deltaSVM score was predicted using 
the model from HCT-116 (a colorectal cancer cell line)44. Second, for these 
variants, we obtained their rsID, the nearest gene Ensemble ID and histone 
modification information from the UCSC Genome Browser and HaploReg version 
4.145. On GTEx eQTL website46, we used their rsID, Ensemble ID to test eQTLs 
in tissue “Colon Sigmoid.” Box plots and p values were automatically generated 
by the webpage. 
 
	 49 
Whole genome sequencing and variant calling 
Samples were collected through multiple studies from the Genetics and 
Epidemiology of Colorectal Cancer Consortium. 1187 samples were genotyped 
with different Illumina genotyping arrays as well. At the University of Washington 
Sequencing Center, sequencing reads were generated, were aligned to the 
human reference genome (GRCh37 assembly47) using BWA48 (v0.6.2 for Year 1 
and 2, v0.7.10 for Year 3). After the alignment, samples were delivered to the 
University of Michigan for variant calling. 
 
On Year 3, to minimize batch effect coming from different versions of aligners, 
we performed a re-alignment for all samples. All BAM files were first converted 
back to FASTQ using BamToFastQ49, then re-mapped to the human reference 
genome (GRCh37 assembly with decoy sequences as available from the 1000 
Genomes Project) using BWA-MEM50 v0.7.12. After this re-alignment, base 
qualities were recalibrated and duplicated reads were flagged with BamUtil51. We 
reviewed the summary metrics generated using QPLOT52 for each sample. We 
used LASER53 for sample ancestry inference, and verifyBamID54 for estimating 
contamination level. Population outliers and contaminated samples were 
identified but still included in variant calling. 
 
Every year, variant call was performed together with all the samples that were 
delivered before. In total, three rounds of variant calls were performed during 
2013 to 2016. On Year 1 and Year 2, we used GotCloud55 pipeline to detect 
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SNPs and Indels. In brief, GotCloud automatically separate the analysis into 
many small jobs that are distributed on a high-performance computing (HPC) 
cluster. This pipeline includes annotating variants with various calling features, 
and both hard filters and a support-vector machine (SVM) classifier filter based 
on these features. Additionally, on Year 2, we used GenomSTRiP56 to detect 
large deletions. We made a customized script to distribute GenomeSTRiP jobs 
on our HPC cluster. In Year 3, we used VT57 to detect SNPs and Indels, and 
used an customized GotCloud-like pipeline for job distribution and variant filter. 
Finally, using the list of high-quality sites, we performed LD refinement for 
detected genotypes using the haplotype-aware calling algorithm in BEAGLE58. 
The final list of variants was annotated with SNPeff59. 
 
Results 
Genome-wide association analysis 
In our large-scale meta-analysis, we successfully replicated many previous 
findings, especially in European populations (Table S3.2). After excluding regions 
with known risk SNPs, two signals remained at the level of p < 5x10-8, and four 
clusters of signals remained at the level of p < 5x10-7 (Table 3.1). 
 
At the level of p < 5x10-8, we detected a novel signal at 7p12.1 (rs115561508, 
MAF=0.1, P=3.6x10-9) in an intergenic region, 120 Kb downstream of the stop 
codon of gene POM121L12. This gene has been reported as mutated in a rare 
cancer, Muscinous neoplasms of the appendix (MNA)60. We also detected a 
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novel signal at 9q21.12 (rs138140376, MAF=0.003, P=1.9x10-9), which is a multi-
allelic SNP; the other alternative allele was not significant in meta-analysis 
(MAF=0.0003, P=0.55). Rs138140376 is intronic to gene TRPM3, and 178 Kb 
downstream of gene KLF9. The relationship between these two genes and 
colorectal cancer has been reported in some experimental studies61-64, but until 
now no GWAS studies have identified this relationship. Both rs115561508 and 
rs138140376 do not have nearby genome-wide significant SNPs, with the 
secondary lowest p value in their regions at the 10-6 level (Figure S3.6A,B). 
 
At the level of p<5x10-7, the two regions, 2p24.2 (rs78115417, MAF=0.007, 
P=4.1x10-7) and 5q35.1 (rs555044933, MAF=0.004, P=1.7x10-7) both had a rare 
significant SNP at the intergenic region. There is little LD information in these two 
regions (Figure S3.6C,D). However, in the other two regions, 1p21.3 and 
6p21.31, we observed strong clusters of signals (Figure 3.2). In 1p21.3 
(rs841684, MAF=0.47, P=1.5x10-7), there were 7 SNPs (rs841684, rs841689, 
rs1098724, rs1098725, rs2798940, rs866365, rs841708, rs1772895) from a 
strong LD block with p values smaller than 5x10-7 (Figure 3.1A). In 6q21.31 
(rs12529688, MAF=0.085, P=2.5x10-7), the lead SNP rs12529688 was in 
complete linkage with other three significant SNPs (rs16877540, rs76489311, 
rs146718198) (Figure 3.1B). Rs12529688 is intronic to the promoter region of 
FKBP5, which has altered expression level in many different tumors65. 
Additionally, one experimental study has shown that FKBP5 suppresses the 
proliferation of colorectal adenocarcinoma66. 
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In the gene-based test, we tested 18,677 genes using coding variants only. With 
a Bonferroni corrected genome-wide significant threshold at p = 2.7x10-6, we 
identified one gene with p value above the threshold and two genes with p values 
near the threshold (Figure S3.5). Among them, POU5F1B (P = 2.3x10-12) and 
SH2B3 (P = 4.5x10-6) have been reported as associated with colorectal cancer in 
many previous studies2,3,5,7,9,13. HAO1 (P = 5.0x10-6) contains 10 coding SNPs, 
and none of these SNPs reached a genome-wide significant threshold in single-
variant meta-analysis (Table S3.3, Figure S3.7). A Korean GWAS study showed 
the correlation between HAO1 and childhood leukemia67, but no previous studies 
have shown this gene’s correlation with colorectal cancer. An East Asian GWAS 
study68 identified a known risk SNP, rs2423729, which is 51 Kb away from the 
HAO1 transcription start site, as associated with colorectal cancer.  However, in 
our meta-analysis, it was not significant (P = 0.01). 
 
Functional annotation 
We constructed an optimized fGWAS model that integrated three genomic 
annotations: exon, synonymous and stop gain (Table S3.4A). We estimated PPA 
for each genome block and each SNP to measure how likely a SNP is to be 
causal and how likely a genome block is to contain a causal SNP for colorectal 
cancer, respectively. Thirteen regions and 10 SNPs within them reached the 
threshold of causality of PPA > 0.2 (Table S3.5). 
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Regions at 1p22.1-1p21.3 (PPA=0.36), 6p21.31 (PPA=0.36), 7p12.1 (PPA=0.74) 
and 9q21.12(PPA=0.84) contained our newly identified significant signals. In our 
meta-analysis, the region at 4q22.2 (PPA=0.20) did not have genome-wide 
significant signals, with is consistent with the lack of reports about colorectal 
cancer-associated variants in this region. The other 8 regions all contained at 
least one previously identified risk SNP. 
 
Among the 10 SNPs with PPA>0.2, rs115561508 (PPA=0.73) and rs138140376 
(PPA=0.83) are our newly identified genome-wide significant signals. Others are 
previously identified SNPs or within the same LD block of the known risk SNPs. 
Additionally, rs841684 at region 1p22.1-1p21.3, with PPA of 0.16, is near the 
significant threshold of causal SNPs. It is worth notice that in region 15q13.3, we 
prioritized two SNPs in GREM1 gene body with significant PPA: rs1406389 
(PPA=0.28, meta-analysis p=2.0x10-10) and rs2293581 (PPA=0.23, meta-
analysis p=2.5x10-10). In previous studies, both SNPs were previously identified 
as causal variants in this region69,70, and therefore a nice positive control for our 
approach. 
 
Sequence function prediction and expression analysis 
As we constructed fGWAS models with three tissues, GWAS signals were more 
enriched in DNaseI peaks from HCT-116 (a colorectal cancer cell line) from 
ENCODE database than from the control cell line GM12878 (Table S3.4B). We 
applied the deltaSVM model constructed from HCT-116 DNAseI peaks to our 
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imputed dataset, and generated DNaseI sensitivity prediction scores for each 
variant. Most scores were around zero, with a few variants having extreme 
scores, indicating their potential functionality (Figure S3.8). 
 
To prioritize potential functional candidates, we combined the information from 
genome-wide meta-analysis and DNaseI sensitivity prediction. We extracted 22 
SNPs with both low meta-analysis p values and predicted higher DNaseI 
sensitivity. In Colon Sigmoid tissue, half of the 22 SNPs have the allele-specific 
expression data of nearby genes in the GTEx database. After testing allelic-
specific expression of these 11 SNPs, we obtained 4 signals (rs72894784, 
rs34645899, rs62072496, rs1741635) with expression p value smaller than 0.05 
(Table S3.6, Figure S3.9 A-D). 
 
Among the 4 signals, the first one, rs72894784, is in the same LD block as the 
genome-wide significant signal rs146718198 (meta-analysis p=2.7x10-7), and in 
this block we found 4 SNPs with p value at 10-7 level. The second signal, 
rs34645899, (meta-analysis p=7.0x10-5, eQTL p=2.6x10-6) was still significant 
even after multiple-testing correction. The SNP is intronic to ATF1, a gene 
reported as associated with carcinoma and melanoma9. A known risk SNP, 
rs11169552, is 46Kb upstream of rs34645899, but does not show strong 
correlation with ATF1 allelic-specific expression (eQTL p=0.076). This may be an 
interesting finding because the region has extensive LD and it is still unclear 
which gene is the effector gene. The third signal, rs62072496, is 4 Kb upstream 
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of LLGL1, a gene crucial in Drosophila neurogenesis71. There are no significant 
meta-analysis signals or known risk SNP in this region. The fourth signal, 
rs1741635, is 17KB downstream of known risk SNP rs2427038 and rs4925386. 
All these three SNPs are in the coding region of the colorectal cancer associated 
gene, LAMA572. However, the two known SNP did not show a significant 
correlation with the LAMA5 expression level. 
 
Variant calling from the whole-genome sequenced samples 
We generated whole-genome shotgun sequencing data for 3,061 unrelated 
individuals. 10 of them are African Americans (all from Year 1) and the rest are 
Europeans. The average fold coverage of the genome is 6.6, 4.7, 35.2 from Year 
1 to Year 3 (Figure 3.2A). Insert sizes are relatively consistent across samples 
(Figure 3.2B,C). We performed quality control, re-alignment, variant calling and 
LD refinement that efficiently handled this large dataset (see Methods for details). 
 
In Year 3 call set, we identified 46.1 million SNPs and 2.6 million Indels from the 
3,061 individuals (Table 3.2A). The average Transitions/Transversions (Ts/Tv) 
ratio of the detected SNPs is 2.37. In each individual, we identified an average of 
3.4 million SNPs and 0.22 million Indels (Table 3.2B). Additionally, we observed 
an average of 10.3 thousand singletons and 47.7 thousand rare variants of 
frequency <0.5% in Year 3 deep samples, which is much higher than the 
numbers in Year 1 and Year 2 low-coverage samples, with an average of 4.6 
thousand singletons and 39.3 thousand rare variants per sample (Figure S3.10). 
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For quality accessment, we compared genotypes from sequencing and microchip 
across 7,767 sites in 1,857 individuals. The average error rate is 0.30%.  
 
In the 48.7 million variants discovered, 47.1% SNPs and 49.4% Indels are in 
protein coding regions. 0.25% Indels are predicted to cause coding frameshift. 
Compared to other sequencing studies, 58.2% of our identified SNPs exist in 
dbSNP build 145. At the same time, 46.4% of our identified SNPs and 40.6% 
Indels overlap with 1000 Genome Phase 3 findings73. 
 
Discussion 
In this large-scale meta-analysis on HRC imputed data, we identified six regions 
and one gene that were significantly associated with colorectal cancer. In region 
7p12.1 and 9q21.12, there were two SNPs with p values lower than the genome-
wide significant threshold of 5x10-8. In 2p24.2 and 5q35.1, there were two rare 
SNPS with p values lower than the 5x10-7. In these four regions, there is little LD 
information and no other significant signals. In 1p21.3 and 6q21.31, there were 
two clusters of signals with p values lower than 5x10-7, and these signals 
included directly genotyped SNPs. These findings make these two regions better 
candidates than the other four regions. 
 
Without replication analysis, it is hard to tell if these signals are true. In addition, 
unless the sample size is extremely large, it is very difficult for rare variants to 
reach the genome-wide significant threshold. Thus, with the current available 
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data, we performed extra analysis to prioritize potentially functional variants, 
aiming to obtain more information from the current dataset. We observed 
substantial enrichment of significant p values in exon regions. We predicted 
several potentially causal SNPs in both novel regions and known regions. By 
combining meta-analysis, sequence function prediction and eQTL data, we 
highlighted four potentially functional variants as affecting nearby gene 
expression levels. It is worth notice that in known risk regions, some of these 
highlighted functional SNPs are not previously known risk SNPs, but are other 
SNPs that are in the same LD block. 
 
From 3,061 whole-genome sequenced individuals, we generated a dataset of 
48.7 million variants. From this mixture of high and low-coverage data, e 
obtained an excessive number of rare variants from higher coverage samples. 
About half of the variants are novel to dbSNP, which means the dataset is very 
likely to contain undiscovered risk loci for colorectal cancer. 
 
In conclusion, our association analysis results indicate that a larger variant set 
with higher marker density not only provides more potential for identifying novel 
variants, but also gives us a new understanding of variant functions in previously 
identified risk regions. To reliably discover novel risk variants, especially rare 
variants, an even larger sample size is necessary. Our whole-genome 
sequencing variant dataset has been contributed to the HRC project as well, and 
will be further used for more analysis for colorectal cancer. 
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Figures and Tables 
 
Figure 3.1 LocusZoom on the two regions with cluster of SNPs of P < 5×10-7 
  
(A) The region at 1p21.3. Lead SNP rs841684 with P = 1.5x10-7. In total, 
there are 8 SNPs with P = 1.5x10-7, all in the same LD block. Extensive 
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(B) The region at 6p21.31. Lead SNP rs12529688 with P = 2.5x10-7. There 
are 4 SNPs with P = 1.5x10-7, all in the same LD block, with multiple 
genes clustered in this block. Three out of the four SNPs are upstream 
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Figure 3.2 Sequencing characteristics of GECCO WGS samples 
We show distributions of (A) mean depth (B) medium insert size (C) standard deviation of insert size. Overall the 
distributions of sequencing characteristics are consistent, with no obvious outliers. Year 3 samples are deeply sequenced, 
with more consistent insert size than the low-coverage sequenced samples from Year 1 and Year 2. 




Table 3.1 Newly identified SNPs associated with colorectal cancer with P values less than 5×10-7 
 




       SNP with P < 5x10-8 




9q21.12 rs138140376 73207739 C/T 3.00E-03 1.90E-09 0.61 TRPM3 Intron 
      SNP with P < 5x10-7 
1p21.3 
rs841684 95057293 T/C 
0.47 
1.48E-07 
0.95 F3 Intergenic 
rs841689 95059247 G/A 2.00E-07 
rs1098724 95064512 T/C 1.58E-07 
rs1098725 95064950 A/G 1.58E-07 
rs2798940 95065092 C/T 2.04E-07 
rs866365 95065110 G/C 2.12E-07 
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rs841708 95065633 T/G 1.49E-07 
rs1772895 95068347 A/G 4.32E-07 
2p24.2 rs78115417 190304106 C/T 7.20E-03 4.10E-07 0.53 WDR75 Intergenic 










rs76489311 35507418 G/A 4.32E-07 
Intergenic 
rs146718198 35511735 G/A 2.74E-07 
rs12529688 35512925 C/T 2.50E-07 Intron 
 
aPosition is based on assembly GRCh37 
 bAllele is annotated as reference allele / alternative allele 
 cAnnotated with UCSC Genome Brows
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Table 3.2 Summary of Year 3 variant calls 
(A) Summary of variant sites detected from 3,061 individuals across all years. 
dbSNP Ts/Tv was calculated from the variants found in dbSNP, while the novel 









1000G Phase 3 








1000G Phase 3 
2.64 M 57.0% 0.37 0.25% 40.6% 
 
(B) Average numbers of variants across all 3,061 individuals. 
Type #Variantsa #Singleton #Doubleton #HETb #ALTc 
SNP 3.43 M 4,708 3,130 2.11 M 1.33 M 
Indel 216 K 198 107 139 K 77 K 
a Average number of variants in one individual 
b Average number of variants with heterozygous genotype in one individual 






Supplementary Figure 3.1 Ancestry inference of the 26,903 individuals 
Dark spots represent the tested individuals while the other colors represent the 
reference population from Human Genome Diversity Project (HGDP) reference 
panel. Most individuals are estimated as Europeans, with only a few outliers at 





Supplementary Figure 3.2 QQ plot of meta-analysis p values across all 22 
million imputed variants 
The meta-analysis has a well-controlled inflation rate. The significant signals 
mostly come from the known risk loci associated with colorectal cancer (shown in 





Supplementary Figure 3.3 QQ plot for single variant association analysis 
on each genotyping platform 
(A) AffyMetrix (n=1,124) (B) Initial (n=5,924) 
(C) CCFR USC (n=2,151) (D) OmniExpress (n=5.986) 
(E) CytoSNP (n=10,908) (F) CCFR Subset3 (n=811) 
We observed strong association signals in larger dataset (B) (D) and (E), 
especially in common variants. Due to the limitation of sample size, p values of 
rare variants are deflated, especially in smaller studies (A) (C) and (E) 
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Supplementary Figure 3.4 Manhattan plot of single-variant meta-analysis 
22 million variants from were tested. We observed strong cluster of signals at 




Supplementary Figure 3.5 Manhattan plot of the gene-based test 
18,677 genes were tested with Burden test assuming equal weights. We 





Supplementary Figure 3.6 LocusZoom plots on the rest four regions with P 
< 5 × 10-7 
There lacks other significant signals in these four regions except for the lead 
SNP. No LD block was observed in these regions. 
 
(A) The region at 7p12.1. The lead SNP is rs115561508 with P = 3.6x10-9 and 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































53.1 53.2 53.3 53.4
Position on chr7 (Mb)
	 70 
 
(B) The region at 9q21.12. The lead SNP is rs138140376 with P = 1.9x10-9 
and MAF = 0.03%. The lead SNP, located at the coding region of TRPM3, 
is a multi-allelic SNP. Its other allele is not significant in meta-analysis, 
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(C) The region at 2p24.2. The lead SNP is rs78115417 with P = 4.1x10-7 and 
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(D) The region at 5q35.1. The lead SNP is rs55504933 with P = 1.7x10-7 
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Supplementary Figure 3.7 LocusZoom plot of HAO1 
The gene HAO1, with P = 5.0 × 10-6 includes 10 coding SNPs in gene-based 
test. None of the SNPs showed evidence of significance in meta-analysis. The 
significant P value of the gene is due to the concordant effect direction and 






Supplementary Figure 3.8 Distribution of HCT-116 deltaSVM scores 
With a model built from ENCODE colon cancer cell line HCT-116 DNaseI 
sensitivity peak data, we generated deltaSVM scores for 3,000 SNPs from the 
GECCO HRC imputed dataset. SNPs were selected based on LD pruning from 





Supplementary Figure 3.9 eQTL expression of the nearby genes of the 4 
variants with P < 0.05 at Colon Sigmoid 
(A) rs72894784 tested on TEAD3. Meta-analysis P = 1.0 × 10-5, eQTL P = 3.3 
× 10-2. Heterozygotes have lower expression level, while data is 
insufficient to decide expression level of homozygotes. 
(B) rs34645899 tested on ATF1. Meta-analysis P = 8.7 × 10-5, eQTL P = 3.3 × 
10-2. Significant expression level differences were observed across the 
three genotypes, with the alternative allele positively associated with 
expression level. 
(C) rs62072496 tested on LLGL1. Meta-analysis P = 7.2 × 10-5, eQTL P = 1.1 
× 10-2. Substantial lower expression was observed in heterozygotes 
compared with the reference genotype. 
(D) rs1741635 tested on LAMA5. Meta-analysis P = 2.4 × 10-6, eQTL P = 4.5 
× 10-2. Homozygous alternative genotypes have substantial lower 
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Supplementary Figure 3.10 Singleton and rare variant counts per individual 
(A) Singletons of SNPs and Indels per individual. Year 3 (deeply sequenced) 
has more singletons discovered than Year 1 and Year2 (low-coverage 





(B) Rare variant (MAF < 0.5%) counts per individual. Year 3 (deeply 
sequenced) has more rare variants discovered. African Americans in Year 1 
have high counts of rare variants. A few samples have been truncated during 








Supplementary Table 3.1 Study information 
 















398 413 52 54 
Human1Md
uo 






ARCTIC Case-control Canada 769 665 65 52 Affy Chips 













Case-control United States 87 125 65 45 
VITamins And 
Lifestyle 
















MEC Cohort United States 328 346 63 46 
Nurses' Health 
Study 






NHS Ad Cohort United States 513 578 57 100 
Physicians' 
Health Study 

































Supplementary Table 3.2 Meta-analysis results on previously identified CRC risk loci 
Position/Gene SNP Positiona Alleleb MAF P value R2c Population 
1q25.3/LAMC1 rs10911251 183081194 A/C 0.43 5.5E-06 0.92 European 
1q41 
rs6691170 222045446 T/G 0.03 3.6E-01 0.91 European 
rs6687758 222164948 G/A 0.20 2.4E-02 1.00  
2q32.2 rs11903757 192587204 C/T 0.16 2.6E-03 0.85 East Asian 
3p14.1/LRIG1 rs812481 66442435 G/C 0.48 5.1E-04 0.99 
Asian, 
European 
3p22.1/CTNNB1 rs35360328 40924962 A/T 0.15 1.4E-06 0.94 European 
3q26.2/TERC rs10936599 169492101 C/T 0.24 5.2E-01 0.99 European 
6p21 rs1321311 36622900 A/C 0.25 1.9E-01 1.00 
African 
American 
6q26.27/SLC22A3 rs7758229 160840252 T/G 0.32 4.5E-01 1.00 Asian 
8q23.3/EIF3H rs16892766 117630683 C/A 0.08 5.6E-11 0.99 European 
8q24/MYC rs10505477 128407443 A/G 0.49 7.9E-12 0.97 European 
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rs6983267 128413305 G/T 0.48 2.8E-12 0.98  
rs7014346 128424792 A/G 0.38 1.1E-11 1.00  
9p24 rs719725 6365683 A/C 0.38 8.4E-05 0.99 European 
10p14 rs10795668 8701219 G/A 0.31 4.4E-02 1.00 European 
10q22.3/ZMIZ1-
AS1 






rs11190164 101351704 G/A 0.26 2.8E-04 0.97 European 
10q25.2/VTI1A/T
CF7L2 








rs174537 61552680 G/T 0.32 1.4E-04 0.95  
rs4246215 61564299 G/T 0.34 5.4E-04 0.95  
rs174550 61571478 T/C 0.32 8.6E-05 0.97  
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rs1535 61597972 A/G 0.33 9.3E-05 0.99  
11q13.4/POLD3 rs3824999 74345550 G/T 0.48 1.6E-05 1.00 
Asian, 
European 





rs10774214 4368352 T/C 0.38 9.1E-03 0.96 East Asian 
rs3217810 4388271 T/C 0.13 3.8E-09 0.79  
rs3217901 4405389 G/A 0.42 2.4E-06 0.90  
rs10849432 6385727 T/C 0.11 2.5E-02 0.97  
12q13.13 
rs7136702 50880216 T/C 0.35 1.5E-03 0.87 European 
rs11169552 51155663 C/T 0.26 1.3E-02 1.00  
rs3184504 111884608 C/T 0.49 1.1E-06 0.99  
rs59336 115116352 T/A 0.49 3.4E-06 0.96  
rs73208120 117747590 G/T 0.09 1.3E-05 0.94  
14q22.2/BMP4 rs4444235 54410919 C/T 0.48 4.4E-05 0.99 European, 
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East Asian 
rs1957636 54560018 T/C 0.40 1.4E-02 1.00  
15q13/CRAC1/H
MPS/GREM1 
rs16969681 32993111 T/C 0.19 1.9E-02 0.98 European 
rs4779584 32994756 T/C 0.20 4.5E-09 0.97  
rs11632715 33004247 A/G 0.48 3.3E-03 0.99  
16q22.1/CDH1 rs9929218 68820946 G/A 0.29 5.9E-03 1.00 European 
17p13.3 rs12603526 800593 C/T 0.02 1.4E-02 0.86 East Asian 
18q21/SMAD7 rs4939827 46453463 T/C 0.47 8.1E-11 0.98 European 





rs1800469 41860296 G/A 0.31 1.4E-01 0.99 East Asian 
rs2241714 41869392 C/T 0.32 1.5E-01 0.97  
20p12.3/BMP2 
rs961253 6404281 A/C 0.36 1.1E-05 0.99 
East Asian, 
European 
rs4813802 6699595 G/T 0.35 1.0E-05 0.94  
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aPosition is based on assembly GRCh37 
bAnnotated as reference allele / alternative allele 
cImputation R-square from Minimac3 
20q13.3 rs6066825 47340117 A/G 0.36 1.0E-02 0.98 European 
20q13.33/LAMA5 rs4925386 60921044 C/T 0.30 4.6E-03 1.00 European 
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Supplementary Table 3.3 SNPs included in the Burden test of HAO1 
Ten coding SNPs were included in the Burden test of gene HAO1. None of them 
is genome-wide significant, but over half of them have low p values in single-
variant test. 
	
SNP Position Allele MAF 
Single-variant p 
value 
rs34249643 7864284 T/C 0.024 2.0E-03 
rs138358725 7866188 C/A 8.0E-04 0.72 
rs573481520 7866189 G/A 0.033 2.3E-03 
rs201216901 7866210 C/T 0.033 2.3E-03 
rs150881591 7866376 T/C 4.0E-03 0.66 
rs139675589 7875820 G/A 4.0E-03 0.34 
rs146825169 7886834 A/G 2.4E-03 6.0E-03 
rs142998832 7886869 C/T 2.0E-03 0.80 
rs201859601 7915210 C/A 0.030 0.044 





Supplementary Table 3.4 Parameter estimates from fGWAS model 
 
(A) Ridge parameter estimates from fGWAS model. 
fGWAS model was first built with six annotations separately: exon, intron, 
nonsynonymous, synonymous, stop gain, stop loss. Then annotations were 
added and dropped under a cross-validation model, until the model likelihood 
was maximized. Penalty was adjusted to maximize an ridge likelihood. The final 
model included three annotations: exon, synonymous and stop gain, with exon 











(B) Tissue-specific enrichment in DNaseI sensitive regions, estimated by 
fitting fGWAS models using peak information from each cell line separately. 
For HCT-116 and CACO-2, we only used consensus peaks between the two 
replicates. From the fGWAS models, the colon cancer cell line HCT-116 has 
higher enrichment than the control cell line GM12878. No significant 
enrichment was observed in another colon cancer cell line CACO-2, possibly 
because of the low data quality and inconsistency of peaks between its two 
replicates 
 
Cell line # Peaks Enrichment (95%CI) 
GM12878 (Duke) 121127 3.1E-12 (6.3E-21~67) 
HCT-116 93332 0.54 (2.1E-09~99) 
CACO-2 55623 3.1E-11 (6.4E-20~213) 
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Supplementary Table 3.5 SNPs and genome blocks with causality predicted by fGWAS 
PPA > 0.2 was used as the threshold for screening potentially causal genome blocks. If the chunk doesn’t have such 
SNPs with PPA > 0.2, we show the SNP with highest PPA in this chunk. 
Region Chunk Chunk PPA SNP SNP PPA SNP P value 
1p22.1-1p21.3 94644828-95289080 0.36 rs841684 0.16 1.5E-07 
4q22.2 94491587-95040993 0.20 rs2618731 0.01 1.1E-06 
6p21.31 35219926-35785860 0.36 rs11545925 0.04 9.6E-07 
7p12.1 53086094-53536962 0.74 rs115561508 0.73 3.6E-09 
8q23.3-8q24.11 117072454-117720230 1.00 
rs16892766 0.65 5.6E-11 
rs16888589 0.28 1.3E-12 
8q24.11 117720250-118306941 0.32 rs139444083 0.13 6.7E-08 
8q24.21 127948781-128453248 1.00 rs12682374 0.37 1.2E-12 
8q24.21 130622915-131195299 0.76 rs62525036 0.02 1.2E-07 
9q21.12 72785759-73425880 0.84 rs138140376 0.83 1.9E-09 
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15q13.3 32378406-33312613 1.00 
rs1406389 0.28 2.0E-10 
rs2293581 0.23 2.5E-10 
18q21.1 46285923-46858626 1.00 
rs4939567 0.21 5.5E-12 
rs2337113 0.30 3.9E-12 
rs11874392 0.28 4.1E-12 
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Supplementary Table 3.6 eQTL test on predicted DNaseI sensitive sites 
11 SNPs were tested in Colon Sigmoid at GTEx Portal Website. Nearest genes were decided through HaploReg 
v4.1. Four sites have eQTL P < 0.05. 
 




P value  
Nearest gene 




9.99E-06 2.45 0.033 TEAD3 
rs146718198 35511735 2.74E-07 -2.32 0.59 FKBP5 
8q24.11 rs117982378 117707559 0.04 1.45E-05 -2.24 0.34 EIF3H 
8q24.21 
rs62524989 130817869 0.20 1.23E-06 2.64 0.73 GSDMC 
rs62525041 130830724 0.18 2.09E-07 3.32 0.31 RP11-473O4.5 
12p13.2 rs145997566 12785302 0.03 9.28E-05 -2.22 0.32 CREBL2 
12q13.12 rs34645899 51201749 0.40 8.68E-05 2.30 2.6E-06 ATF1 
17p11.2 rs62072496 18124743 0.20 7.18E-05 -2.19 0.011 LLGL1 
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17q22 rs7226124 55030689 0.18 5.44E-05 2.21 0.37 COIL 
20q13.33 rs1741635 60938197 0.21 2.35E-06 2.17 0.045 LAMA5 
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Advances in array genotyping and next-generation sequencing technology have 
greatly reduced the cost of variant detection, and as a result, generated 
unprecedented amounts of genomic variants from population-scale studies. To 
search for causal variants, the genome-wide association approach that surveys 
the whole genome without pre-requisite knowledge has been the major trend1-3. 
 
Recently, meta-analysis in GWAS analysis has been successfully applied in 
many large-scale human genetics studies2-5. Meta-analysis is the statistical 
procedure for combining data from multiple studies6. In ideal situations, the 
performance of modern meta-analysis methods provides equivalent power to that 
																																																								
        This work in Chapter 4 will be submitted as: 
       Chen S, …, Abecasis G. “RAREMETAL2: a more efficient and flexible tool for meta-analysis”. 
       Yang J, Chen S, Abecasis G. “Improved score statistics for meta-analysis in gene-level     
association studies”. 
       Part of this work in Chapter 4 has been submitted as: 
       Zhan X*, Chen S*, Jiang Y, Liu M, …, Vrieze S, Abecasis G, Liu D. “Meta-analysis of 
Sequence-based association studies in the presence of multi-allelic sites”. (* equal contribution)	
	 105 
of joint-analyses that require sharing of individual level data (and which are often 
much more cumbersome to execute)7. 
 
Discovery of these association signals has been enabled by rapid improvements 
in meta-analysis methods and tools5,7-10. Among these tools, RAREMETAL10 is 
one of the most widely used ones, with over hundreds of downloads and several 
successful applications to large consortium studies. However, during the real 
practice, we found that in a few non-ideal situations, the underlying assumptions 
of the standard meta-analysis method may be violated, resulting in biased 
approximation. Below are three common scenarios with violation of meta-
analysis assumptions in real datasets: 
 
1. In standard meta-analysis, one assumption is that within-study phenotypic 
mean and variances are equal to those in joint studies7,11. Yet this assumption is 
not true for some situations, for example, in meta-analysis that combines 
traditional case-control. Studies (with case-control ratio typically close to 1) with 
biobank and population-based studies (with case-control ratio typically much 
larger).  Although weighing summary statistics from each study by their effective 
sample size may provide some adjustment and reduce the power loss, this 
weighing strategy will fail for gene-based tests, because the within-study score 
statistics are related to sample size. 
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2. Compared to the traditional linear mixed models (LMMs), general linear mixed 
model (GLMMs) provides more calibrated results in some situations12,13 and has 
been used more often in recent years. A violation of the meta-analysis 
assumption occurs when combining score statistics generated from those old 
LMM models and those from the newly developed GLMM models. A few studies 
have indicated the systematic bias in the meta-analysis method of summing 
within-study score statistics from these two models, but little research has been 
conducted to address this challenge14. 
 
3. The standard method for generating summary statistics suffers substantial 
power loss in sites with more than one alternative allele (typically named as 
multi-allelic sites). Exome Aggregation Consortium (ExAC) shows that 8% of the 
variants in the human exome are multi-allelic15. However, most analysis method 
can only model effects of one reference and one alternative allele. As a result, 
these multi-allelic SNPs are usually analyzed as separated sites, with the 
reference allele and one alternative allele on each site. As the multi-allelic 
information is ignored, this approach may lead to substantial power loss in both 
single-variant meta-analysis and gene-based test, especially for datasets with 
some individuals having heterozygous genotypes of two different alternative 
alleles. 
 
Here, we implemented several new methods into RAREMETAL to better address 
these challenges: First, we implemented a new method that, rather than simply 
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summing summary statistics across studies, also accounts for variation in 
phenotypic means across studies, also accounts for variation in phenotypic 
means across studies. Second, we implemented a new method that transforms 
LMM generated summary statististics to be numerically equivalent to those from 
GLMMs. This method can additionally help to analyze family-based datasets 
where GLMM parameters are difficult to estimate. Third, we re-designed 
RAREMETAL’s data structure, making it accommodate multi-allelic sites 
correctly. At the same time, we implemented a new method that jointly analyzes 
the effects of multiple alleles rather than the traditional method that analyze 
multiple alleles separately. 
 
Additionally, as the genetics studies datasets becomes larger and larger, there is 
a growing need of optimizations on the speed and disk space usage of the 
software. To match this need, we also improved RAREMETAL, and its 
companion package RAREMETALWORKER (which is used to generate 
summary statistics as RAREMETAL’s input) in the software engineering level. 
With the improvements, the new version taking 7 times less disk space to store 
covariance matrix files, and uses 30% less time to run meta-analysis. 
 
Methods 
Score statistics for individual studies 
Consider a meta-analysis with K studies and N samples in total. Each study has 
nk samples genotyped in mk variants. Let Yk denote the nk×1 phenotype vector; 
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Gk denote the nk×mk genotype matrix (centered and normalized); Xk denote the 
nk×(qk + 1) augmented covariate matrix with first column set to 1 and the others 
encoding qk covariates. 
 
In some practical uses, covariates may need to be regressed out before fitting 
the model. To do this, we first fit covariates against the phenotypes under a linear 
model: 
!! = !!!! + !! 
Then we denote 
!! = !! − !!!! 
When covariates need to be regressed out, Yk is to be replaced by the residual, 
!!. 
 
For a specific SNP i, we denote its score statistics in study k as (Ui,k, Vi,k). We 
denote the meta-analysis score statistics as (Ui,meta, Vi,meta). Using the standard 










Improved score statistics for unbalanced studies 
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Consider the situation with unbalanced studies. An exact meta-analysis score 
statistics can be derived as: 












Here !! represents the deviation between phenotype mean in study k and the 
overall phenotype mean. fi,k represents minor allele frequency (MAF) of this site i 
in study k, and fi represents its overall MAF. !!! is the residual variance of 
phenotypes in study k, and the joint residual variance is estimated as: 






Combine score statistics from LMMs and GLMMs 
For association analysis in study k, we assume the underlying model is a 
generalized linear model: 
!"#$% !" !! = 1 = !!,!!!"##,! + !!!! + !!"##,! + !!"##,! 
 However, a standard linear mixed model is use for association analysis: 
!! = !!,!!!"",! + !!!! + !!"",! + !!"",! 
Where the coefficient can be estimated from the score statistics: 
!!"",! = !!"",!!! !!"",! 
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Through Taylor expansion and approximation on variance components for rare 








1+ !!!!! ! !" !!  
!!~! 0, !"# !!"",! + !"# !!"",!  
With this estimated correction term Ck, the score statistics from the LMM can be 
transformed to those from GLMMs: 
!!"##,! = !!!!"",! 
!!"##,! = !!!!!"",! 
Using a standard meta-analysis method, these transformed score statistics can 
be summed with score statistics from other studies analyzed using GLMMs. 
 
Jointly modeling allele effects of multi-allelic sites 
Traditionally, for a variant with L alternative alleles, the reference allele is coded 
as 0, while the alternative alleles are consequently coded as 1 to L. Here, 
instead, for an individual j in study k at site i, we encode the genotype as a L-
length vector Gi,j,k=(Gi,j,k,1,Gi,j,k,2,…,Gi,j,k,L), where the lth entry is the number of the 
lth alternative alleles. 
 






+ !!!! + !!"",! + !!"",! 
And score statistics can be derived as: 




Having the phenotype variance denoted as !!!, we have the variance-covariance 
matrix for multi-allelic sites represented as: 
!!,!~!,! = !!! !!,!! !!,! − !!,!! !! !!!!! !!!!!!!,!  
Testing of lth allele can be controlled on the effect of the remaining L-1 alternative 
alleles, using a method similar to conditional meta-analysis. We can then derive 
the score statistics for testing the effect of allele l as: 








Similarly, !!,!,!|!! can be estimated as the covariance between the score statistics 
of the lth allele and the remaining L-1 alternative alleles. To test the effect of the 
lth allele, a standard meta-analysis can be performed by summarizing !!,!,!|!!, 
!!,!,!|!!. 
 
In gene-based tests, !!,!|!! can be used together with other score statistics from 
bi-allelic sites. In addition, to calculate covariance between a multi-allelic site i 
and a bi-allelic site i’, we have: 
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!"# !!,!,!|!! ,!!!,! = !"# !!,! ,!!!,! − !!,!,!|!!!!,!,!!~!,!,!!!! !"# !!,! ,!!!,!  
Here !!!,! is calculated under the traditional bi-allelic model. 
 
Optimization on covariance matrix files 
The original RAREMETALWORKER stored a covariance matrix as a gzipped text 
file, one variant per line, using the format of chromosome, position, variant in the 
same LD block, and variant covariance in the same LD block. In the field of 
variant names and variant covariance, values were comma separated. With such 
method, the disk usage is scaled as O(n2), becoming extremely huge for large 
datasets.  
 
To reduce the disk space usage, we changed the storing method for covariance 
matrix files in the new version. First, for a specific variant, we search for its 
nearby variants by tracing back the hash table of loaded variants, instead of 
directly recording nearby variants as a field in the file. Second, for a covariance 
with an extremely small value comparing to covariance from other nearby 
variants, it would be approximated to zero. Third, we only store index and 
covariance of variants with non-zero covariance. 
 
It is worth noting that with this approximation a covariance matrix may not be 
positive semi-definite, or even become a zero matrix. To make downstream 
analysis possible, we add an identity matrix to the covariance matrix so that the 




To test the performance of our new method in unbalanced studies, we simulated 
20,000 haplotypes of 5 KB length for 5 European populations using COSI16. Then 
we sampled genotypes of 339 variants in 100,000 individuals. We simulated 
dichotomous phenotypes according to the standard logistic regression model 
with half randomly selected causal variants in a randomly selected region of 100 
variants. We set the intercept term subject to 1% disease prevalence and the log 
odds ratio as !!! !!!!  , where C is a given constant. Here we simulated 
phenotypes with the constant C as zero. For balanced studies, each study had 
300 cases and 300 controls. For unbalanced studies, the number of cases for the 
five studies were (60, 180, 300, 420, 540), and the numbers of controls for the 
five studies were (540, 420, 300, 180, 60). Two covariates (C1, C2) were 
simulated for each study. C1 was a binary covariate subjected to a Bernoulli 
distribution of P = 0.5; C2 was a continuous covariates subjected to N(0,1). 
Covariate coefficients were taken as 0.1 in the logistic model. 
 
To test performance of our new method in combining LMMs and GLMMs, we 
simulated another dataset of 1000 variants based on the standard logistic 
regression model: 
! = !"#$%&''( !
!"
1+ !!"  
Each element of the genetic effect vector ! followed a normal distribution: 
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!!~!!! 0 + 1− !! ! 0, !!!  
Here we set !!! is as 0.033, and set half of the variants as causal variants 
(!!=0.5). 
 
To simulate multi-allelic sites, we randomly sampled from the 219,680 multi-
allelic sites in ExAC15 project. With the MAFs from these sampled sites, we 
simulated 1000 samples, with genotypes sampled from a multinomial distribution. 
Similar to previous datasets, we simulated genetic effect of each allele from the 
distribution of ! 0, !!! . 
 
Results 
Optimized methods in unbalanced studies 
We simulated a test dataset of both balanced and unbalanced studies, with 3,000 
individuals and 339 variants. We tested the original and the new versions of 
RAREMETAL on this dataset. Joint analysis was also performed as the golden 
standard for evaluation.  
 
In the meta-analysis of balanced studies, the original and the new version show 
similar performance as the joint analysis. As we expected, in this situation, with 
the correction term for between-study phenotypic variation of zero, the new 
method shrinks to the original method. In the meta-analysis of balanced and 
unbalanced studies, the new method shows similar performance as the joint 
analysis, while the original method suffers substantial power loss (Figure 4.1). 
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Combining statistics from LMMs and GLMMs 
We generated summary statistics using LMM on 4 simulated studies, and meta-
analyzed the summary statistics using the new version of RAREMETAL, the 
method proposed by Pirinen et al14, and the original version. Joint analysis was 
performed on these simulated studies using GLMM as a golden standard. The 
new version achieves a equivalent association analysis power as the joint 
analysis (Table 4.1). The original method shows substantial power loss, 
compared to the joint analysis. Association detection power of Pirinen et al’s 
method is higher than the original method but lower than our new method. These 
results indicate a correction of summary statistics in such scenario is necessary. 
 
Jointly modeling allele effects of multi-allelic sites 
Sampled from the real data in ExAC Project, we simulated a multi-allelic dataset 
to test the performance of our new method and the traditional method that 
analyzes each allele separately. In different levels of genetic effects, our new 
method shows higher power than the standard method (Table 4.2). For example, 
at the genetic effect of 0.25, the power from the traditional method is 0.62, 11% 
lower than the power from our new method of 0.66. 
 
Software engineering improvements 
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We performed single-variant meta-analysis for 69,362 markers across 11,998 
unrelated individuals (European ancestry) in 20 studies using RAREMETAL. The 
new version takes 11.5 seconds while the original version takes 17.2 seconds. 
 
To test performance of optimizing covariance matrix files, we randomly sampled 
the Haplotype Reference Consortium (HRC)17 Panel imputed variants from the 
GECCO18 “Omni chip” (detailed description of the dataset is in Chapter 3). For a 
10 Mb randomly sampled region from chromosome 9 with 145,017 variants, we 
generated covariance matrix files using the original version and new the version 
of RAREMETALWORKER. The file size of the original and the new version are 
4.9 GB and 0.73 GB, respectively. Using the two covariance matrix files and 100 
randomly generated variant groups, we performed burden test19 respectively. 
The resulting p values from the two covariance matrix files were highly 
concordant (Figure 4.2). 
 
Discussion 
In this chapter, we have described a major update to our software RAREMETAL 
that brings in software enginering improvements and several useful new methods 
for rare variant analysis. Using simulated datasets, we show the new update in 
addition preserve the software’s ability to meta-analysis in unbalanced studies, 
multi-allelic sites and GLMMs. 
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Our new method for unbalanced studies, which incorporates cross-sample 
phenotypic variation into calculating score statistics, greatly rescued the power 
loss of the standard method. For now, the method only applies to unrelated 
samples. It remains as a future direction of adjusting this method to datasets with 
family structures. 
 
Our new method of combining score statistics generated by LMMs and GLMMs 
has better power than the standard method that naively combines score statistics 
from these different models altogether. From our simulation, we show that this 
method provides a feasible way of analyzing datasets with dichotomous traits, 
especially for family-based data where GLMM model parameter is difficult to 
estimate. Alternatively, the dataset can be fit with LMMs first, and later in meta-
analysis RAREMETAL can transform these summary statistics to those from 
GLMMs. 
 
Our new method for multi-allelic sites jointly model effects of multiple alleles, 
rather than the traditional method that analyzes multi-allelic sites separately. 
From the simulated dataset, we observed substantial power loss for the 
traditional method, which may indicate an under-estimation of the phenotyp-
genotype association of multi-allelic sites in previous studies. Considering the 
huge amount of multi-allelic variants in large and deeply sequenced datasets, it 
will be very promising to apply our new version of RAREMETAL to these real 
datasets to re-evaluate the effects of multi-allelic sites. 
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Additionally, we made software engineering improvements to RAREMETAL and 
its companion package RAREMETALWORKER, making meta-analysis and 
summary statistics storage more efficient. The reduced covariance matrix file 
size will enables us to do gene-based test in a subset of non-coding regions. 
However, to perform gene-based tests genome-widely, the optimized covariance 
matrix file is still a huge disk space cost. Considering the increasing number of 
variants in sequencing studies and imputation reference panel, a further 
reduction of covariance matrix file size is necessary. Possible solutions include 
binary coding and customized compression, but more experiments need to be 
conducted to evaluate their compression rate and real time cost. Nevertheless, 
our current improvement in RAREMETALWORKER is a promising step towards 
this direction. 
 
In conclusion, we updated our meta-analysis software RAREMETAL with 
software engineering improvements and several new methods. With these 
improvements, we believe RAREMETAL will be even more useful for meta-
analysis in future genetics studies. 
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Figures and Tables 
 
Figure 4.1 P values from the standard and the optimized method for 
unbalanced studies in simulated dataset 
Meta-analysis power the standard and the optimized method is compared 
against the joint analysis, which is used as golden standard for evaluating 
association detection power.  
(A) In balanced studies, the three methods are equivalent. Data points of the 
standard and the optimized method perfectly overlap. 
(B) In unbalanced studies, the standard method suffers substantial power loss 
while the optimized method is unaffected (still showing similar power as 
the joint analysis). 





Figure 4.2 Burden test p values from the standard and the optimized 
covariance matrix 
We sampled a 10 Mb genomic region and simulated genes for Burden test. The 
two methods showed almost the same P values for Burden tests, indicating the 






Table 4.0-1 Power of VT test for LMM analyzed studies   
Four methods were compared. The original method naively combines summary 
statistics from LMMs together. Our new method and Pirinen et al’s method scale 
LMM-derived summary statistics before combining. The joint analysis analyzes 
the pooled samples under GLMM. The power was evaluated under significance 
threshold α = 2.5 × 10-6 in 1 million replicates. The optimal method has similar 














0.3 0.35 0.32 0.28 0.35 
0.5 0.35 0.33 0.28 0.35 
0.7 0.36 0.31 0.28 0.36 




Table 4.0-2 Power from the standard bi-allelic analysis and the new multi-
allelic analysis method on multi-allelic sites 
Genotypes were simulated based on MAF of multi-allelic sites in 7 sub-
populations from the ExAC project from a multinomial distribution. Alternative 
allele effects were simulated from a normal distribution with the variance equal to 
the given genetic effect. The total sample size is 10,000. Association power was 
evaluated under significance threshold α = 5 × 10-8 in 1 million replicates. The 
new multi-allelic method shows better power than the standard method under 








0 4.9 × 10-8 4.8 × 10-8 
0.1 0.32 0.37 
0.25 0.46 0.51 
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Summary and Discussion 
 
Summary 
Advances in genotyping technology have led to the discovery of an 
unprecedented amount of variants, while association analysis has become the 
major approach to finding disease-related genes and loci out of these millions or 
even billions of variants. The findings from these revolutionized technology and 
methodology have been evolving our understanding of human genetics 
disorders. In this dissertation, I have contributed to discovering disease-related 
variants and genes, both in terms of method development and in terms of real 
data analysis. 
 
In chapter 2, I described a likelihood-based method, LIME, to detect MEIs (a 
specific type of novel insertion) from sequencing data. The method naturally 
accommodates cross-sample heterogeneity, and generates genotype likelihood 
to measure the probability of each MEI event. Tested by both simulated data and 
real data, LIME shows better performance than existing methods, especially in 
low-coverage data. In addition, by applying LIME to samples from the Sardinia 
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Whole Genome Sequencing Project, we generated a MEI dataset with functional 
impact prediction on each MEI. We believe LIME will help to generate better-
quality MEI dataset from other sequencing studies as well. 
 
In chapter 3, I presented a genome-wide association analysis on colorectal 
cancer in 26,903 individuals imputed onto the Haplotype Reference Consortium 
(HRC) reference panel. We identified 6 regions of potential associations with 
colorectal cancer. We replicated many previous findings on common and high 
penetrant variants related to colorectal cancer as well, showing the reliability of 
our method. By incorporating functional annotation, sequence function prediction 
and online eQTL data, we highlighted additional loci for potential causality and 
impact on nearby gene expression. Although it is difficult to obtain new significant 
variants in absence of extremely large dataset, our analysis provides new 
insights into association analysis under limited sample size. 
 
In chapter 4, I developed several improvements to the meta-analysis software, 
Raremetal. We implemented a new meta-analysis method that incorporates 
cross-study phenotypic variation, and thus solves the problem of substantial 
power loss in unbalanced studies. We improved the method of meta-analyzing 
statistics from LMMs and GLMMs. This improvement also allows single studies to 
be analyzed with LMMs, since the score statistics can be later transformed as 
equivalent to those from GLMMs. We improved the coding scheme and analysis 
method of multi-allelic variants. With the new method, we got better power for 
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multi-allelic variants than the previous method. Finally, we optimized the storage 
of covariance matrix files from the software, making the file size much smaller 
than previous versions. With these improvements, the software Raremetal now 
more precisely captures the association between variants and diseases in 
complicated situations, and become more flexible and efficient on real datasets. 
 
Future Directions 
There still remain many questions in sequencing and association analysis, which 
could be statistically and computationally challenging. In the future, solutions or 
improvements in the following areas will lead to new genetic discoveries. 
 
First, software LIME can be improved to incorporate the information from longer 
reads. In the future, read length of the short read approach may continue to 
increase, and it will become crucial to incorporate the information conveyed by 
those longer reads. One approach will be to incorporate the re-mapping score 
from MEI consensus sequence into likelihood calculation, replacing the current 
approach that only uses a binary standard. On the other hand, long read 
approaches, such as PacBio, and short read approaches may be combined to 
generate better calling of MEIs. To incorporate the information from both 
approaches, we need to have a better estimation of sequencing error rates from 
long read approaches, and then improve the likelihood calculation method so that 
information from both approaches will be incorporated. 
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Second, software LIME can be applied to more datasets to perform association 
tests for detected MEIs. Although a few studies have more or less implied the 
association between MEIs and certain diseases, there is very little research 
focused on MEIs’ disease causality on a genome-wide scale. Since LIME 
generates genotype likelihood for each MEI, we can apply LIME to large datasets 
and perform LD-aware refinement the detected MEIs together with SNPs and 
Indels in order to improve MEI detection quality. With the combined variant 
dataset, we could perform association tests and obtain a comprehensive view of 
different variants’ roles in disease causality. At the same time, special 
considerations are required for such analysis. Variant calling is always 
computationally intensive. In variant calling stage, we need to optimize the 
pipeline for both the short variant calling and MEI calling. In the phasing stage, 
we need a systematic review of the scale of likelihood between different types of 
variants; otherwise the phasing will be driven by those variants with extreme 
scale of genotype likelihood. In association analysis, since the larger variants 
may have higher impact on gene functions, we may need an optimized weighing 
scheme for short variants and MEIs. 
 
Third, a replication analysis for the imputed GECCO data should be performed. 
Replication analysis is always the golden standard to test if an association signal 
is true. Moreover, with increased sample size, we may obtain significant signals 
for those associated rare variants, which previously were insignificant simply 
because of the limitation of sample sizes. Additionally, with more collaboration 
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between consortiums, we could incorporate samples from other studies as 
additional controls; as a result, this approach will increase the effective sample 
size as well as the association detection power. 
 
Conclusion 
New technology always brings up new challenges. With the increasing size of 
genetics data, appropriate analysis methods and efficient statistical tools will be 
in great need. In this dissertation, I have proposed improved methods for 
analyzing genetics data, and performed an analysis on a real dataset to discover 
associated variants for colorectal cancer. I believe these newly developed 
methods and approaches will facilitate analysis of genetics data, and provides 
insight to future genetics researches. 
 
 
